ArticleDiscover oncology2026
Integrative analysis identified the key role of LAG3 in T cell exhaustion in glioma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overcoming resistance in glioblastoma immunotherapy: lessons from the past and opportunities for the future.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint expressed on the surface of T cells. We conducted a comprehensive molecular characterization and clinical analysis of LAG3 expression in gliomas. Across the CGGA and TCGA glioma datasets, we observed that LAG3 expression increased with higher glioma grade. Further investigation into the molecular subtypes revealed that LAG3 exhibited the highest expression in the Mesenchymal subtype, similar to other immune checkpoints. CIBERSORT analysis showed a significant positive correlation between LAG3 expression and macrophages, suggesting LAG3’s involvement in shaping the immune microenvironment. Single-cell data indicated that LAG3 expression appeared to be complementary pattern to other immune checkpoints, implying multiple mechanisms of T cell exhaustion. Importantly, clinical data analysis demonstrated that elevated LAG3 expression is an independent poor prognostic factor for patient survival. These findings suggest that LAG3 may play a crucial role in regulating the immune microenvironment in gliomas and contribute to T cell exhaustion, alongside other immune checkpoints such as the PD-L1/PD-1 pathway. As such, LAG3 represents a potential therapeutic target for glioma immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.